TSE:BN

Brookfield Corp (BN.TO)

61.85
+0.83 (1.36%)
as of Jul 10, 2026, 6:26:58 pm Market Open.
283 watching
0
Investor Insights
star iconJul 10, 2026, 12:00 am

This summary was created by AI, based on 51 opinions in the last 12 months.

Brookfield Corp (BN-T) has garnered a mix of opinions from experts, reflecting its complex structure and diverse asset management focus. Many analysts appreciate its core strengths in utilities and infrastructure, emphasizing its strong cash flow potential and favorable positioning in the market. Despite concerns over opaque financing and the recent challenges faced by private credit, several experts recommend BN as a core holding due to its historical earnings growth and anticipated demand for private equity. The stock is currently seen as trading at a discount to its net asset value (NAV), suggesting potential for upside. Analysts point to its robust real estate portfolio and solid management as key factors for long-term investors, though some express caution due to its exposure to market volatility and interest rate sensitivity.

consensus icon
Consensus
Buy
valuation icon
Valuation
Undervalued
review icon
Similar
BAM,BN
TOP PICK

One of the world's foremost managers of long-duration assets, like private equity, renewable energy and utilities. They have assets around the world like the UK. They have size, scale and diverse funding. Are also a fine asset manager. Are capital-lite. Flows of funds into alternative assets are outstripping funds into stocks and bonds, even with these interest rates. Their shareholder returns are 15% compounded over the last 25 years. That means a $1 in 1998 is $31 today, including dividends.

(Analysts’ price target is $59.48)
STRONG BUY

Unfortunately, Brookfield is looking like the old Brascan empire, a plate of spaghetti, where they spin off all these entities, then buy them back and it's hard to keep track of how many there are. That said, BAM and BN-T are grossly undervalued. The market is overreacting to the impact of commercial real estate BN-T, in particular. 

DON'T BUY

He hasn't warmed up to the Brookfield companies. This restructuring is a bit of a shell game. He prefers a pure play stock. But if he prefers the Renewables stock the most given its growth prospects.

PAST TOP PICK
(A Top Pick Aug 14/23, Down 12%)

Stock overhang due to commercial real estate portfolio. Still thinks overall - real estate will be strong. Interest rates will put pressure on company in mid term. Long term is a strong business. Excellent ability to raise money. Will continue to own shares. 

BUY

Insurance business very strong. Ability to raise capital very good. High quality management team. Diverse array of assets. Would hold for the long term. 

SELL
Sell BAM and BN to buy Brookfield Reinsurance

He's very negative and expects 17% downside. No, negative trend yet, but doesn't like the Brookfield companies. Why are there three Brookfield companies in the index? $40.85 is his target.

BUY

It has good assets and good access to capital. This means it can buy assets with declining prices and there are global opportunities as well. It is at a good entry point to buy for the long term.

BUY

Two really well-run companies. 

BN is the parent company for all the subsidiaries. A wonderful compounder. Negative sentiment around real estate holdings, which are high quality and global. Capital allocation opportunities will benefit shareholders. Loves it, he'd buy right here.

For BIP.UN, a wonderful income opportunity. You get growth and income. He'd be a buyer of this one, too. Valuation discount to BN. 

BUY

What's hurt it is their large commercial property portfolio, though an excellent AAA one. BN trading at a 30% discount to NAV. Now is a good time to look at BN at these levels. Historically, they've narrowed the NAV over time.

BUY ON WEAKNESS

All the Brookfield offerings are extremely well-managed companies. Fair amount of leverage built in, as demonstrated by recent volatility. When the price is depressed, that's the time to look. Expects dividend increases. All are good, and BN is probably one of the better ones.

WEAK BUY
BN vs. BIP.UN

Problem in last year has been its real estate holdings with interest rates going up as much as they have. Sometimes the satellites are the better way to play. Both work, but BIP.UN is the better choice right now with it being as cheap as it is and growing at 10%. 

BUY

Many dislike this for owning a lot of real estate, but if you add up all the publicly traded companies that BN owns, you get the real estate for free. A worthwhile investment and you should buy. The best-managed conglomerate in Canada.

PAST TOP PICK
(A Top Pick Nov 09/22, Up 2%)

They spun off the asset manager, and this is the core company. The tickers are confusing. This is the mothership to its affiliate companies and stocks. This is a great compounder over 3 decades and continues to be so. He continues to buy this.

DON'T BUY
BN vs. BAM

Over the next year interest rates should reverse, so we should see some good pickup in stocks that are yield plays. Not looking for big gains on these types of stocks.

Chart for BN shows the common pattern of a peak in 2021, and then a decline in 2022. Lots of correlation with the market. Now the stock's bottoming out, and we'll have to see where the next trend is. Decent support around $41, so you're OK if it stays above that. So many other stocks to choose from, he wouldn't touch this one.

BAM has been consolidating. Hard to trade, as the trading range is quite narrow. It's a buy from a yield perspective. If it breaks above $48 and hits a new level, a whole new round of buyers will come in. Holds it for some clients as a way to diversify.

TOP PICK

It is a good long term investor holding shares of other Brookfield companies as well as having an insurance arm. The stock price is reflecting concerns over real estate exposure. However the market is giving it zero value for this and its commercial holdings are at the premium end which are not as affected as the lower end holdings. There have been a couple of defaults but this is not a concern. Brookfield has provided good returns over time.
Buy 9  Hold 2  Sell 1

(Analysts’ price target is $60.07)
Showing 121 to 135 of 177 entries